Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.6081
Abstract: 6081Background: Sorafenib and lenvatinib are oral MKIs approved for the treatment of RAI-R DTC; however, there is no consensus on when patients with asymptomatic RAI-R DTC should start treatment wi... read more here.
Keywords: patients asymptomatic; treatment; interim analysis; second interim ... See more keywords
Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Translational Cancer Research"
DOI: 10.21037/tcr-21-2417
Abstract: Background Differentiated thyroid cancer (DTC) is the most common thyroid tumor, and the cells of DTC patients can lose the ability to differentiate in their natural state or during treatment and develop radioiodine-refractory DTC (RAI-R… read more here.
Keywords: rai dtc; thyroid carcinoma; dtc; refractory ... See more keywords